The choice of treatment is best determined by the sensitivity of these genetic markers.
BRCA1 and BRCA2 provide protection of mature, functioning breast and ovarian cells.
Mutations in BRCA1 or BRCA2 identify a client’s risk for cancerous cell development in breast tissue.
The prognosis of breast cancer is most successful when these markers are inherited mutations.